Answers are grounded in this paper and cite their sources.
OBJECTIVE: The aim of the study was to investigate the efficacy of ultrasound-guided platelet-rich plasma in reducing sacroiliac joint disability and pain. DESIGN: Prospective nonrandomized interventional study analyzing 50 patients with low back pain secondary to sacroiliac joint dysfunction. Platelet-rich plasma was injected into the sacroiliac joint under ultrasound guidance. Oswestry Disability Index and Numeric Rating Scale were measured at baseline, 2 wks, 4 wks, 3 mos, and 6 mos after injection. RESULTS: The mean reduction in Oswestry Disability Index and Numeric Rating Scale scores were significantly reduced at 6 mos after injection compared with baseline values (mean = -9.79%, 95% CI = -6.06 to -13.52) and (mean = -1.94, 95% CI = -1.14 to -2.78), respectively. All timeframes showed significant mean reduction compared with baseline, but overall improvement tapers off after 4 wks with no statistically significant reduction from 4 wks to 3 mos or 3 to 6 mos. CONCLUSIONS: Ultrasound-guided platelet-rich plasma injections in the sacroiliac joint are effective at reducing disability and pain with most improvement seen within 4 wks after injection and with sustained reduction at 6 mos.
No takes yet. Share an insight, caveat, or question.
Wallace et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: